Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia

Not Applicable

Completed

Conditions: Chronic Sinusitis

Interventions: Device: Propel Nova Sinus Implant

Registration Number: NCT02228720

Lead Sponsor: Intersect ENT

Brief Summary: This is a feasibility study is to assess the performance, safety and initial signals of efficacy of the drug-eluting Propel Nova Sinus Implant when used in chronic sinusitis patients undergoing sinus surgery of peripheral sinus ostia.

Detailed Description: This is a prospective, single-center, single-arm, open label feasibility study aiming to enroll at least 10 patients and a maximum of 15 patients to achieve 30 treated sinuses. The objective of this feasibility study is to assess the performance, safety and initial signals of efficacy of the drug-eluting Propel Nova Sinus Implant when used in chronic sinusitis (CS) patients undergoing sinus surgery of peripheral sinus ostia.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 15

Inclusion Criteria

Patient is ≥ 18 years of age.
Patient is willing and able to comply with protocol requirements.
Patient has CS as confirmed by CT scan and defined as symptoms lasting longer than 8 consecutive weeks in duration with inflammation of the mucosa of the nose and paranasal sinuses.
Patient's condition and the planned intervention will involve at least two and a maximum of four peripheral sinuses (frontal or maxillary sinuses or combination of both).
Patient is a candidate for a planned intervention involving sinus surgery in the operating room or office setting.
Patient has nasal polyps no greater than grade 2.
Patient with nasal polyps greater than 2 are eligible after their reduction/removal during ESS without significant complications that would confound the study results and leaving the patient's anatomy amenable to sinus implant placement, as judged by the operating physician.
Female patients of child-bearing potential must not be pregnant and must agree to not become pregnant during the course of the study.
Female patients of child-bearing potential must agree to use consistent and acceptable method/s of birth control during the course of the study.
CS diagnosis confirmed and documented by CT Scan within 6 months of the procedure.
Patient has a minimum total CT stage (Lund-Mackay method) of 6.
Patient has disease in frontal and/or maxillary sinuses confirmed by CT scan.
Planned ESS includes bilateral ethmoidectomy (if judged necessary), frontal sinus surgery using Draf II (A or B) dissection and/or balloon dilation, with minimum of 5-mm diameter opening created. In the case of maxillary sinus surgery, traditional antrostomy or balloon dilation, with or without removal of uncinate process, should be performed with minimum of 5-mm diameter opening created.
Technique used for frontal or maxillary sinus surgery was the same on both sides (e.g. surgical dissection alone bilaterally, balloon dilation alone bilaterally, or both bilaterally)
Septoplasty for access to the ostio-meatal complex is permitted.

Exclusion Criteria

Patient has presence of grade 3 or 4 polyposis, unless removed during surgery and preceding implant placement.
Patient has presence of adhesions/scarring grades 3 or 4, unless removed during surgery and preceding implant placement.
Patient has known history of immune deficiency (e.g., IGG subclass deficiency or IGA deficiency, HIV).
Patient has concurrent condition requiring active chemotherapy and/or immunotherapy management for the disease (e.g., cancer, HIV, etc.).
Patient has oral-steroid dependent condition such as COPD, asthma or other condition.
Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate.
Patient has clinical evidence of acute bacterial sinusitis (e.g. acute increase in purulent discharge, fever, facial pain etc.).
Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g. bone erosion on prior CT scan, necrotic sinus tissue, etc.).
Patient has evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the 90-day period.
Patient is currently participating in another clinical trial.
Patient has history of insulin dependent diabetes mellitus.
Patient has previously undergone ESS and experienced a CSF leak or has residual compromised vision as a result of a complication in a prior ESS procedure.
Patient has known dehiscence of the lamina papyracea.
Patient has evidence of active viral illness (e.g., tuberculosis, ocular herpes simplex, chickenpox or measles).
Significant complication during the current peripheral ostia surgery/such as excessive blood loss, CSF leak or punctured lamina papyracea.
Current surgical intervention (operating room or office setting) is aborted for any reason.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Propel Nova Sinus Implant	Propel Nova Sinus Implant	Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days

Primary Outcome Measures

Name	Time	Method
Device Placement Success Rate	Baseline Procedure	Defined as successful access to and placement of the Propel Nova Sinus Implant in the frontal or maxillary sinus ostium within two attempts. Calculated as a proportion where the numerator is the number of successful device placements and the denominator is the number of attempted sinuses.

Secondary Outcome Measures

Name	Time	Method
Degree of Inflammation	Baseline, Day 30, Day 90	Inflammation visual analog scale (VAS) from 0 (no visible inflammation) to 100 (severe inflammation, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes)
Sino-Nasal Outcome Test (SNOT) 22	Baseline, Day 30, Day 90	Validated, disease-specific, symptom-scoring instrument consisting of 22 questions, each scored by the patient on a scale of 0 (no problem) to 5 (problem as bad as it can be), resulting in a maximum total score of 110
Ostial Patency	Baseline, Day 30, Day 90	Ostial patency grading scale from 0 (patent) to 1 (Occluded/Restenosed)
Adhesion/Scarring Grade 2 & 3	Baseline, Day 30, Day 90	Adhesion/scarring grading scale from 0 (No visible granulation/scarring), 1 (Minimal amount of scarring/contraction observed but non-obstructing the frontal or maxillary sinus ostium), 2 (moderate amount of obstructive scar tissue/contraction present in the frontal or maxillary sinus ostium), 3 (Significant scar tissue/ contraction causing obstruction of the frontal or maxillary sinus ostium)

Trial Locations

Locations (2): South Florida ENT Associates
🇺🇸
Miami, Florida, United States
Ohio Sinus Institute
🇺🇸
Dublin, Ohio, United States
South Florida ENT Associates
🇺🇸Miami, Florida, United States